Wedbush Maintains Neutral on Abivax, Raises Price Target to $110
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ: ABVX ) with a Neutral and raises the price target from $90 to $110.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.